CRNX Quote, Financials, Valuation and Earnings

GT Biopharma, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of --. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 64.68%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are larger than GT Biopharma, Inc. quarterly revenues of --. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,955.94x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of 31.72%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Eli Lilly & Co.'s return on equity of 106.26%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 64.68%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.01%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Eli Lilly & Co..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,955.94x versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -39.75%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 64.68%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 0.21%. Given that Crinetics Pharmaceuticals, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Crinetics Pharmaceuticals, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,955.94x versus 18.03x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sutro Biopharma, Inc. has a net margin of -90972.73% compared to Crinetics Pharmaceuticals, Inc.'s net margin of -586.58%. Crinetics Pharmaceuticals, Inc.'s return on equity of -37.41% beat Sutro Biopharma, Inc.'s return on equity of -10195.04%.

Crinetics Pharmaceuticals, Inc. has a consensus price target of $80.21, signalling upside risk potential of 64.68%. On the other hand Sutro Biopharma, Inc. has an analysts' consensus of $21.00 which suggests that it could grow by 102.31%. Given that Sutro Biopharma, Inc. has higher upside potential than Crinetics Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than Crinetics Pharmaceuticals, Inc..

Crinetics Pharmaceuticals, Inc. has a beta of 0.200, which suggesting that the stock is 79.99% less volatile than S&P 500. In comparison Sutro Biopharma, Inc. has a beta of 1.615, suggesting its more volatile than the S&P 500 by 61.536%.

Crinetics Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sutro Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Crinetics Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sutro Biopharma, Inc. pays out -- of its earnings as a dividend.

Crinetics Pharmaceuticals, Inc. quarterly revenues are $143K, which are smaller than Sutro Biopharma, Inc. quarterly revenues of $9.7M. Crinetics Pharmaceuticals, Inc.'s net income of -$130.1M is lower than Sutro Biopharma, Inc.'s net income of -$56.9M. Notably, Crinetics Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sutro Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Crinetics Pharmaceuticals, Inc. is 2,955.94x versus 2.66x for Sutro Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.